Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969374 | 0.92 | HCRTR1 (0.42) | HCRTR1HCRTR2LMNAMAPTCTSA | |
| SCHEMBL1970015 | 0.90 | RORB (0.41) | LMNAMAPTCTSAPDE4BLTC4S | |
| SCHEMBL1968513 | 0.89 | HCRTR1 (0.41) | HCRTR1HCRTR2WDR5LMNAMAPT | |
| SCHEMBL1967954 | 0.88 | HCRTR1 (0.40) | HCRTR1HCRTR2LMNAMAPTCTSA | |
| SCHEMBL1968066 | 0.88 | LMNA (0.39) | HCRTR1HCRTR2LMNAMAPTCTSA | |
| SCHEMBL1968387 | 0.84 | HCRTR1 (0.48) | HCRTR1HCRTR2WDR5LMNAMAPT | |
| SCHEMBL1970670 | 0.81 | HCRTR1 (0.44) | HCRTR1HCRTR2LMNAMAPTPDE4B | |
| SCHEMBL1965921 | 0.81 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL1966277 | 0.81 | HCRTR1 (0.38) | HCRTR1HCRTR2WDR5MAPTCTSA | |
| SCHEMBL1971740 | 0.78 | KDM4E (0.38) | MAPTPDE4BLTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885WDR5 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.